Korea's two diagnostics companies, NGeneBio Co. and LabGenomics Co., signed a memorandum of understanding (MOU) on Thursday to cooperate in the field of next-generation sequencing (NGS) services.
The two companies will work together in developing NGS-based services both in the domestic and the US market.
For this, they intend to take advantage of a US Clinical Laboratory Improvement Amendments (CLIA) Lab, which LabGenomics plans to acquire.
After taking over a CLIA, LabGenomics, together with NGeneBio, plans to develop LDT services that applied their advanced diagnostic technologies to CLIA Lab's diagnostic process.
NGeneBio will supply LabGenomics with NGS diagnostics products, bioinformatics software, and laboratory-developed test (LDT) services. It will export NGS products to the US once LabGenomics completes the acquisition of the CLIA Lab.
Meanwhile, the biggest shareholder LabGeneomics signed in September a contract to sell its managerial rights to Luha Private Equity, South Korea, at 90 billion won. Capitalizing on 94.1 billion won in cashable assets, Luha plans to promote genetic testing molecular diagnosis services and new overseas business.
Write to In-Hyuk Park at hyuk@hankyung.com
LabGenomics Co., a molecular diagnostics company, said on Tuesday that it has signed an agreement with digital healthcare company Humanscape to develop a direct-to-consumer genetic testing business in Southeast Asia and the United States.Humanscape runs Mamitalk, a pregnancy and parenting plat
BankSalad CEO Kim Tae-hun poses for a photo at the company’s Seoul headquarters BankSalad Co., once known as a fintech company that develops banking apps, added a new vertical last year that has witnessed robust demand. The South Korean startup is now categorized as a MyData business
(Courtesy of Getty Images) South Korean direct-to-consumer (DTC) genetic testing companies are rushing to the veterinary diagnostics market where they see greater potential growth than the human diagnostics market, according to industry sources on June 19. Clinomics Inc., a secondary bour